NasdaqGS:ANIK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$613.5m

Last Updated

2021/06/23 14:51 UTC

Data Sources

Company Financials +

Executive Summary

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Anika Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ANIK's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

1.6%

ANIK

-0.6%

US Biotechs

-0.1%

US Market


1 Year Return

26.1%

ANIK

19.7%

US Biotechs

39.0%

US Market

Return vs Industry: ANIK exceeded the US Biotechs industry which returned 20% over the past year.

Return vs Market: ANIK underperformed the US Market which returned 39% over the past year.


Shareholder returns

ANIKIndustryMarket
7 Day1.6%-0.6%-0.1%
30 Day-2.8%3.9%2.6%
90 Day16.7%8.6%8.0%
1 Year26.1%26.1%21.4%19.7%41.2%39.0%
3 Year35.4%35.4%12.2%7.5%62.4%52.3%
5 Year-18.5%-18.5%60.0%47.3%132.3%106.2%

Long-Term Price Volatility Vs. Market

How volatile is Anika Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Anika Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ANIK ($42.51) is trading below our estimate of fair value ($87.1)

Significantly Below Fair Value: ANIK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ANIK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ANIK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANIK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANIK is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Anika Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

101.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ANIK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ANIK's is expected to become profitable in the next 3 years.

Revenue vs Market: ANIK's revenue (14.6% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: ANIK's revenue (14.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANIK's Return on Equity is forecast to be low in 3 years time (5.5%).


Past Performance

How has Anika Therapeutics performed over the past 5 years?

-32.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANIK is currently unprofitable.

Growing Profit Margin: ANIK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANIK is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.

Accelerating Growth: Unable to compare ANIK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANIK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: ANIK has a negative Return on Equity (-9.74%), as it is currently unprofitable.


Financial Health

How is Anika Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ANIK's short term assets ($173.5M) exceed its short term liabilities ($47.0M).

Long Term Liabilities: ANIK's short term assets ($173.5M) exceed its long term liabilities ($38.6M).


Debt to Equity History and Analysis

Debt Level: ANIK is debt free.

Reducing Debt: ANIK had no debt 5 years ago.

Debt Coverage: ANIK has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ANIK has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Anika Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANIK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANIK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANIK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANIK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANIK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Cheryl Blanchard (56 yo)

1.33yrs

Tenure

US$10,096,847

Compensation

Dr. Cheryl R. Blanchard, Ph.D. serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She served as Interim Chief Executive Officer at Anika Therapeutics, Inc. ...


CEO Compensation Analysis

Compensation vs Market: Cheryl's total compensation ($USD10.10M) is above average for companies of similar size in the US market ($USD2.34M).

Compensation vs Earnings: Cheryl's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ANIK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: ANIK's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANIK insiders have bought and sold the same number of shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Anika Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Anika Therapeutics, Inc.
  • Ticker: ANIK
  • Exchange: NasdaqGS
  • Founded: 1983
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$613.499m
  • Shares outstanding: 14.39m
  • Website: https://www.anikatherapeutics.com

Number of Employees


Location

  • Anika Therapeutics, Inc.
  • 32 Wiggins Avenue
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings


Biography

Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company’s joint pain management products inclu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/23 14:51
End of Day Share Price2021/06/22 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.